Assessment of early anthracycline-induced cardiotoxicity and liver injury with T2 and T2* mapping in rabbit models.
Cardiotoxicity
Liver diseases
Magnetic resonance imaging
Rabbits
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
08 Aug 2023
08 Aug 2023
Historique:
received:
28
02
2023
accepted:
13
06
2023
revised:
09
05
2023
medline:
8
8
2023
pubmed:
8
8
2023
entrez:
8
8
2023
Statut:
aheadofprint
Résumé
To evaluate the early prevalence of anthracycline-induced cardiotoxicity (AIC) and anthracycline-induced liver injury (AILI) using T2 and T2* mapping and to explore their correlations. The study included 17 cardiotoxic rabbits that received weekly injections of doxorubicin and magnetic resonance imaging (MRI) every 2 weeks for 10 weeks. Cardiac function and T2 and T2* values were measured on each period. Histopathological examinations for two to five rabbits were performed after each MRI scan. The earliest sensitive time and the threshold of MRI parameters for detecting AIC and AILI based on these MRI parameters were obtained. Moreover, the relationship between myocardial and liver damage was assessed. Early AIC could be detected by T2 mapping as early as the second week and focused on the 7th, 11th, and 12th segments of left ventricle. The cutoff value of 46.64 for the 7th segment had the best diagnostic value, with an area under the curve (of 0.767, sensitivity of 100%, and specificity of 52%. T2* mapping could detect the change in iron content for early AIC at the middle interventricular septum and AILI as early as the sixth week (p = 0.014, p = 0.027). The T2* values of the middle interventricular septum showed a significant positive association with the T2* values of the liver (r = 0.39, p = 0.002). T2 and T2* mapping showed value one-stop assessment of AIC and AILI and could obtain the earliest MRI diagnosis point and optimal parameter thresholds for these conditions. Anthracycline-induced cardiotoxicity could be detected by T2 mapping as earlier as the second week, mainly focusing on the 7th, 11th, and 12th segments of left ventricle. Combined with T2* mapping, hepatoxicity and supplementary cardiotoxicity were assessed by one-stop scan. • MRI screening time of cardiotoxicity was as early as the second week with focusing on T2 values of the 7th, 11th, and 12th segments of left ventricle. • T2* mapping could be used as a complement to T2 mapping to evaluate cardiotoxicity and as an effective index to detect iron change in the early stages of chemotherapy. • The T2* values of the middle interventricular septum showed a significant positive association with the T2* values of the liver, indicating that iron content in the liver and heart increased with an increase in the chemotherapeutic drugs.
Identifiants
pubmed: 37552260
doi: 10.1007/s00330-023-10027-1
pii: 10.1007/s00330-023-10027-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to European Society of Radiology.
Références
Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53(24):2231–2247
doi: 10.1016/j.jacc.2009.02.050
pubmed: 19520246
Felker GM, Thompson RE, Hare JM et al (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342(15):1077–1084
doi: 10.1056/NEJM200004133421502
pubmed: 10760308
Ferreira D, Souza T, Quinaglia T, Neilan TG, Coelho-Filho OR (2019) Assessment of cardiotoxicity of cancer chemotherapy: the value of cardiac MR imaging. Magn Reson Imaging Clin N Am 27(3):533–544
doi: 10.1016/j.mric.2019.04.001
Zamorano JL, Lancellotti P, Rodriguez Munoz D et al (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the european society of cardiology (ESC). Eur Heart J 37:2768–2801
doi: 10.1093/eurheartj/ehw211
pubmed: 27567406
Galán-Arriola C, Lobo M, Vílchez-Tschischke JP et al (2019) Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol 73(7):779–791
doi: 10.1016/j.jacc.2018.11.046
pubmed: 30784671
Hong YJ, Park HS, Park JK et al (2017) Early detection and serial monitoring of anthracycline-induced cardiotoxicity using T1-mapping cardiac magnetic resonance imaging: An animal study. Sci Rep 7(1):2663
doi: 10.1038/s41598-017-02627-x
pubmed: 28572614
pmcid: 5453985
Hong YJ, Kim TK, Hong DY et al (2016) Myocardial characterization using dual-energy CT in doxorubicin-induced DCM: comparison with CMR T1-mapping and histology in a rabbit model. JACC Cardiovasc Imaging 9(7):836–845
doi: 10.1016/j.jcmg.2015.12.018
pubmed: 27236517
Ferreira D, Souza T, Quinaglia AC et al (2018) Anthracycline therapy is associated with cardiomyocyte atrophy and preclinical manifestations of heart disease. JACC Cardiovasc Imaging 11(8):1045–1055
doi: 10.1016/j.jcmg.2018.05.012
Park HS, Hong YJ, Han K et al (2021) Ultrahigh-field cardiovascular magnetic resonance T1 and T2 mapping for the assessment of anthracycline-induced cardiotoxicity in rat models: validation against histopathologic changes. J Cardiovasc Magn Reson 23(1):76
doi: 10.1186/s12968-021-00767-8
pubmed: 34134713
pmcid: 8210390
Tahir E, Azar M, Shihada S et al (2022) Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT. Eur Radiol 32(3):1853–1865
doi: 10.1007/s00330-021-08260-7
pubmed: 34536111
Ichikawa Y, Ghanefar M, Bayeva M et al (2014) Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest 124(2):617–630
doi: 10.1172/JCI72931
pubmed: 24382354
pmcid: 3904631
Tadokoro T, Ikeda M, Ide T et al (2020) Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. JCI Insight 5(9):e132747
doi: 10.1172/jci.insight.132747
pubmed: 32376803
pmcid: 7253028
Anderson LJ, Holden S, Davis B et al (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22(23):2171–2179
doi: 10.1053/euhj.2001.2822
pubmed: 11913479
Bai H, Kong F, Feng K et al (2021) Prussian blue nanozymes prevent anthracycline-induced liver injury by attenuating oxidative stress and regulating inflammation. ACS Appl Mater Interfaces 13(36):42382–42395
doi: 10.1021/acsami.1c09838
pubmed: 34473471
Prasanna PL, Renu K, Valsala-Gopalakrishnan A (2020) New molecular and biochemical insights of doxorubicin-induced hepatotoxicity. Life Sci 250:117599
doi: 10.1016/j.lfs.2020.117599
pubmed: 32234491
Itoh T, Kawabe M, Nagase T, Koike T, Miyoshi M, Miyahara K (2018) Measurements of body surface area and volume in laboratory rabbits (New Zealand White rabbits) using a computed tomography scanner. Exp Anim 67(4):527–534
doi: 10.1538/expanim.18-0028
pubmed: 29998917
pmcid: 6219877
Carpenter JP, He T, Kirk P et al (2011) On T2* magnetic resonance and cardiac iron. Circulation 123(14):1519–1528
doi: 10.1161/CIRCULATIONAHA.110.007641
pubmed: 21444881
pmcid: 3435874
Messroghli DR, Moon JC, Ferreira VM et al (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 19(1):75
doi: 10.1186/s12968-017-0389-8
pubmed: 28992817
pmcid: 5633041
Thavendiranathan P, Wintersperger BJ, Flamm SD, Marwick TH (2013) Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging 6(6):1080–1091
doi: 10.1161/CIRCIMAGING.113.000899
pubmed: 24254478
Voldsbekk I, Groote I, Zak N et al (2021) Sleep and sleep deprivation differentially alter white matter microstructure: a mixed model design utilising advanced diffusion modelling. Neuroimage 226:117540
doi: 10.1016/j.neuroimage.2020.117540
pubmed: 33186715
Willis MS, Parry TL, Brown DI et al (2019) Doxorubicin exposure causes subacute cardiac atrophy dependent on the striated muscle-specific ubiquitin ligase MuRF1. Circ Heart Fail 12(3):e005234
doi: 10.1161/CIRCHEARTFAILURE.118.005234
pubmed: 30871347
pmcid: 6422170
Wu X, Li Y, Zhang S, Zhou X (2021) Ferroptosis as a novel therapeutic target for cardiovascular disease. Theranostics 11(7):3052–3059
doi: 10.7150/thno.54113
pubmed: 33537073
pmcid: 7847684
Cappellini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A (2008) Guidelines for the clinical management of thalassaemia [Internet]. 2nd, Revised. Thalassaemia International Federation, Nicosia (CY)
Perifanis V, Tziomalos K, Tsatra I, Karyda S, Patsiaoura K, Athanassiou-Metaxa M (2005) Prevalence and severity of liver disease in patients with b thalassemia major. A single-institution fifteen-year experience. Haematologica 90(8):1136–1138
pubmed: 16079116
Ware HM, Kwiatkowski JL (2013) Evaluation and treatment of transfusional iron overload in children. Pediatr Clin North Am 60(6):1393–1406
doi: 10.1016/j.pcl.2013.09.003
pubmed: 24237978
Wood JC, Zhang P, Rienhoff H, Abi-Saab W, Neufeld EJ (2015) Liver MRI is more precise than liver biopsy for assessing total body iron balance: a comparison of MRI relaxometry with simulated liver biopsy results. Magn Reson Imaging 33(6):761–767
doi: 10.1016/j.mri.2015.02.016
pubmed: 25708262
Jensen CJ, Jochims M, Hunold P et al (2010) Assessment of left ventricular function and mass in dual-source computed tomography coronary angiography: influence of beta-blockers on left ventricular function: comparison to magnetic resonance imaging. Eur J Radiol 74(3):484–491
doi: 10.1016/j.ejrad.2009.03.027
pubmed: 19375878